DAFNA Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

DAFNA Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.74M	Sell	57,769 -12,846	-18%	-$1.91M	1.86%	13
2026 Q1	$9.3M	Hold	70,615	–	–	2.12%	13
2025 Q4	$10M	Hold	70,615	–	–	2.33%	12
2025 Q3	$9.91M	Hold	70,615	–	–	2.45%	11
2025 Q2	$8.88M	Sell	70,615 -1,000	-1%	-$115K	2.45%	12
2025 Q1	$7.92M	Hold	71,615	–	–	2.25%	14
2024 Q4	$9.78M	Buy	71,615 +2,000	+3%	+$247K	2.48%	13
2024 Q3	$8.02M	Sell	69,615 -2,000	-3%	-$274K	1.89%	18
2024 Q2	$9.86M	Hold	71,615	–	–	2.36%	14
2024 Q1	$9.88M	Sell	71,615 -1,000	-1%	-$137K	2.25%	14
2023 Q4	$9.57M	Sell	72,615 -1,000	-1%	-$115K	2.29%	14
2023 Q3	$8.28M	Sell	73,615 -1,000	-1%	-$105K	2.58%	12
2023 Q2	$7.04M	Hold	74,615	–	–	1.92%	17
2023 Q1	$7.55M	Buy	74,615 +1,494	+2%	+$155K	2.26%	14
2022 Q4	$8.73M	Sell	73,121 -7,034	-9%	-$824K	2.46%	11
2022 Q3	$8.51M	Sell	80,155 -2,500	-3%	-$254K	2.29%	13
2022 Q2	$8.06M	Sell	82,655 -1,000	-1%	-$92.3K	2.2%	11
2022 Q1	$7.84M	Hold	83,655	–	–	2.04%	11
2021 Q4	$7.13M	Sell	83,655 -1,000	-1%	-$92K	1.79%	15
2021 Q3	$8.12M	Buy	84,655 +11,000	+15%	+$1.04M	2.15%	11
2021 Q2	$7.17M	Hold	73,655	–	–	1.5%	16
2021 Q1	$7.16M	Sell	73,655 -18,553	-20%	-$1.95M	1.7%	14
2020 Q4	$8.84M	Buy	92,208 +2,000	+2%	+$193K	2.63%	6
2020 Q3	$8.67M	Buy	90,208 +17,000	+23%	+$1.97M	2.82%	8
2020 Q2	$8.93M	Sell	73,208 -7,000	-9%	-$774K	2.58%	7
2020 Q1	$6.94M	Buy	80,208 +19,200	+31%	+$1.88M	2.9%	9
2019 Q4	$6.56M	Sell	61,008 -3,500	-5%	-$366K	2.25%	11
2019 Q3	$5.81M	Sell	64,508 -100	-0.2%	-$9.34K	2.19%	11
2019 Q2	$5.46M	Buy	64,608 +9,600	+17%	+$788K	2.05%	14
2019 Q1	$4.85M	Hold	55,008	–	–	2.09%	13
2018 Q4	$3.93M	Buy	55,008 +14,000	+34%	+$1.34M	1.95%	16
2018 Q3	$5.04M	Sell	41,008 -4,500	-10%	-$511K	2.07%	13
2018 Q2	$4.47M	Sell	45,508 -9,000	-17%	-$806K	2.09%	13
2018 Q1	$4.52M	Hold	54,508	–	–	2.2%	16
2017 Q4	$4.23M	Hold	54,508	–	–	2.28%	15
2017 Q3	$3.34M	Hold	54,508	–	–	2.07%	12
2017 Q2	$2.51M	Sell	54,508 -4,000	-7%	-$194K	1.79%	15
2017 Q1	$2.53M	Sell	58,508 -7,500	-11%	-$321K	2.14%	16
2016 Q4	$2.56M	Buy	66,008 +2,000	+3%	+$90.5K	2.24%	15
2016 Q3	$3.24M	Sell	64,008 -11,495	-15%	-$572K	2.26%	12
2016 Q2	$3.43M	Sell	75,503 -797	-1%	-$36.7K	2.72%	11
2016 Q1	$3.02M	Buy	+76,300	New	+$3.03M	2.6%	10
2014 Q4	–	Sell	-66,141	Closed	-$1.04M	–	64
2014 Q3	$1.04M	Buy	+66,141	New	+$989K	1.04%	24

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

DAFNA Capital Management's NBIX Position: Q2 2026 in Review

DAFNA Capital Management reduced its Neurocrine Biosciences (NBIX) stake by 18% in Q2 2026, selling an estimated $1.91M and leaving 57,769 shares worth $9.74M. The position accounts for 1.86% of the portfolio, ranked #13.

DAFNA Capital Management first reported a position in NBIX in Q3 2014 and has held it in 43 quarters since. The position peaked at $10M in Q4 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

DAFNA Capital Management held 57,769 shares of Neurocrine Biosciences worth $9.74M as of Q2 2026.
DAFNA Capital Management sold 12,846 Neurocrine Biosciences shares in Q2 2026, an estimated $1.91M.
Neurocrine Biosciences made up 1.86% of DAFNA Capital Management's portfolio in Q2 2026, its #13 holding.
DAFNA Capital Management first reported a position in Neurocrine Biosciences in Q3 2014 and has held it in 43 quarters since.
DAFNA Capital Management's Neurocrine Biosciences position peaked at $10M in Q4 2025.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.